<p><p>The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women. The overall 5-year survival rate is about 97%, making it one of the least lethal cancers. We are experiencing an epidemic
Thyroid Cancer
✍ Scribed by R. Görges (auth.), H.-J. Biersack, F. Grünwald (eds.)
- Publisher
- Springer-Verlag Berlin Heidelberg
- Year
- 2005
- Tongue
- English
- Leaves
- 372
- Edition
- 2
- Category
- Library
No coin nor oath required. For personal study only.
✦ Synopsis
One of the main reasons for publishing this second edition of “T- roid Cancer” is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. The most prominent change in the clinical sciences has been the new classification of thyroid cancer, especially with relation to T1–T3 tumors. Now, tumors with a diameter of up to 2 cm are still classified T1. This new UICC classification (6th edition) follows the classification of the American Society of Pathology. These changes require a modification of the old guidelines. According to the Hedinger classification (1988) tumors with a diameter below 1 cm were classified as “papillary microcarcinoma of the thyroid”. Only in those tumors was total or nearly total thyroidectomy deemed unn- essary and I-131 therapy not a prerequisite for treatment. The majority of the chapters has been updated including references to many new publications. Two new chapters, on I-124 PET and - simetry, have been added. We strongly feel that this second edition of “Thyroid Cancer” is again a state-of-the-art overview of the diagnosis and treatment of thyroid cancer. Bonn, Frankfurt am Main H. -J. Biersack, F. Grünwald Preface to the First Edition Thyroid cancer was first described at the end of the eighteenth c- tury.
✦ Table of Contents
The Changing Epidemiology of Thyroid Cancer....Pages 3-27
Histopathology, Immunohistochemistry, and Molecular Biology....Pages 29-56
Familial Differentiated Carcinoma of the Thyroid....Pages 57-70
The Diagnosis of Thyroid Cancer....Pages 71-81
The Current Surgical Approach to Non-Medullary Thyroid Cancer....Pages 83-92
Radioiodine Therapy for Thyroid Cancer....Pages 95-126
124 I Positron Emission Tomographic Dosimetry and Positron Emission Tomography/Computed Tomography Imaging in Differentiated Thyroid Cancer....Pages 127-138
External Beam Radiotherapy....Pages 139-161
Thyroid Cancer: Treatment with Thyroid Hormone....Pages 163-170
Treatment with Cytotoxic Drugs....Pages 171-186
Redifferentiation Therapy of Thyroid Carcinomas with Retinoic Acid....Pages 187-197
Follow-up of Patients with Well-Differentiated Thyroid Cancer....Pages 199-219
Thyroglobulin as Specific Tumor Marker in Differentiated Thyroid Cancer....Pages 221-237
Functional Imaging of Differentiated Thyroid Cancer....Pages 239-250
Magnetic Resonance Imaging....Pages 251-282
Thyroid Cancer in Chernobyl Children....Pages 283-293
Diagnosis of Medullary Thyroid Cancer....Pages 297-309
Imaging in Medullary Thyroid Cancer....Pages 311-333
Therapy for Medullary Thyroid Cancer....Pages 335-345
Follow-up of Medullary Thyroid Cancer....Pages 347-356
✦ Subjects
Oncology; Nuclear Medicine; Endocrinology
📜 SIMILAR VOLUMES
<p><p>The American Cancer Society recently estimated that about 45,000 new cases of thyroid cancer will be diagnosed in the United States, with three-quarters occurring in women. The overall 5-year survival rate is about 97%, making it one of the least lethal cancers. We are experiencing an epidemic
<p>Because of its relative rarity and favorable outcome, it has not been feasible to assess medical interventions for thyroid cancer using randomized prospective trials. The approach to diagnosis and treatment relies to a great extent on information derived from retrospective studies. Overall progno
<p>The subject of this publication, thyroid cancer, was the topic chosen for the First Symposium on Clinical Oncology, orga nized by the Royal College of Radiologists, London, on 26 and 27 January 1979. The papers collected here are based on the presentations made at that meeting, but have been exp
One of the main reasons for publishing this second edition of "T- roid Cancer" is the fact that the first edition has sold out. Furth- more, during the 4 years following the publication of the first edition in 2001, some progress, mainly in the basic sciences (molecular biology), has been made. The